Spero Therapeutics Secures $105M Financing and in-Licensed SP001

Spero Therapeutics completed a non-recourse financing and in-licensed the anti-CD40L antibody SP001 from Innovent Biologics, advancing it toward a Phase 2 study beginning in 2027, while highlighting $107.9M in cash on hand. This positions the company to address serious, rare inflammatory diseases.